Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

kidney transplant

- PMLiVE

Merck/Pfizer’s cancer immunotherapy latecomer hits a snag

Bavencio fails a key lung cancer trial

Bristol-Myers Squibb (BMS) building

BMS pens massive $3.6bn deal for Nektar cancer immunotherapy

Nektar’s NKTR-214 to be paired with Opdivo and Yervoy in a host of tumour types

- PMLiVE

EC grants MSD’s Prevymis orphan product designation

The product will gain some market exclusivity benefits in CMV infection

- PMLiVE

Dr Fiona Marshall heads up MSD’s new UK research facility

She will be based in London and focus on early bioscience discovery

- PMLiVE

Merck chalks up another win for Keytruda in lung cancer

Becomes the first PD-1 inhibitor to improve OS in NSCLC patients when combined with chemo

- PMLiVE

AZ and Merck & Co get FDA breast cancer nod for Lynparza

It becomes the first PARP inhibitor to be approved outside ovarian cancer

- PMLiVE

Merck closes in on adjuvant melanoma indication for Keytruda

Its immunotherapy could catch up with BMS’ Opdivo if approved

- PMLiVE

UK trumpets life sciences post-Brexit ‘sector deal’

Highlights commitments from GlaxoSmithKline, AstraZeneca and MSD

MSD outlines its AI needs in tech start-up programme

Continues its Velocity Health work with Wayra UK

- PMLiVE

CHMP backs MSD’s CMV infection treatment

Prevymis is set to be available as an injectable and tablets

- PMLiVE

CDC backs GSK’s Shingrix over Merck & Co’s Zostavax

US advisors recommend GSK's shingle vaccine be used instead of Merck's rival product

AstraZeneca AZ

AZ and MSD win FDA priority review for Lynparza in breast cancer

Could become the first PARP inhibitor to be approved in the US for the disease

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links